List of Excipients in Branded Drug CARDENE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Carilion Materials Management	CARDENE	nicardipine hydrochloride	68151-0089	CELLULOSE, MICROCRYSTALLINE
Carilion Materials Management	CARDENE	nicardipine hydrochloride	68151-0089	CORN
Carilion Materials Management	CARDENE	nicardipine hydrochloride	68151-0089	LACTOSE
Carilion Materials Management	CARDENE	nicardipine hydrochloride	68151-0089	MAGNESIUM STEARATE
Carilion Materials Management	CARDENE	nicardipine hydrochloride	68151-0089	METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER
Carilion Materials Management	CARDENE	nicardipine hydrochloride	68151-0089	STARCH, CORN
Chiesi USA Inc	CARDENE IV	nicardipine hydrochloride	10122-314	CITRIC ACID MONOHYDRATE

CARDENE Excipient Strategy and Commercial Opportunities for Nicardipine Hydrochloride

Last updated: October 11, 2026

Cardene is an established nicardipine hydrochloride product with limited conventional exclusivity and a primarily hospital-based commercial opportunity. The strongest excipient opportunities are in preservative-free injectable presentations, ready-to-use bags, dilution-free concentrations, low-sorbate formulations, and packaging systems that improve stability and reduce preparation errors. Oral nicardipine presents a smaller opportunity because generic capsules are established and the original Cardene capsule product is no longer the primary commercial platform.

What is Cardene and which dosage forms are commercially relevant?

Cardene contains nicardipine hydrochloride, a dihydropyridine calcium-channel blocker used to reduce blood pressure, including in acute-care settings requiring intravenous titration. The principal commercial dosage forms are:

Product type	Active ingredient	Primary use	Excipient opportunity
Cardene I.V. injection	Nicardipine hydrochloride	Short-term blood-pressure control in hospitals and intensive-care units	High
Nicardipine capsules	Nicardipine hydrochloride	Chronic hypertension treatment	Moderate to low
Ready-to-use nicardipine infusion	Nicardipine hydrochloride	ICU and perioperative blood-pressure control	High
Premixed pharmacy-compounded bags	Nicardipine hydrochloride	Institutional infusion	Moderate
Novel oral modified-release product	Nicardipine hydrochloride	Chronic hypertension or adherence-sensitive populations	Moderate, but commercially difficult

The intravenous market is the more attractive target because clinical value depends on preparation time, concentration accuracy, compatibility, line management, and storage. Those factors create room for excipient and container-closure differentiation even when the active ingredient is off patent.

What excipients are used in Cardene I.V.?

The Cardene I.V. formulation uses nicardipine hydrochloride in an aqueous system containing sorbitol and citric acid. Hydrochloric acid and sodium hydroxide are used to adjust pH. The product is supplied as a concentrated injection that requires dilution before administration under the approved labeling instructions. [1]

Cardene I.V. excipient profile

Component	Function	Commercial significance
Nicardipine hydrochloride	Active pharmaceutical ingredient	Highly water soluble salt form
Sorbitol	Tonicity and formulation-supporting excipient	Affects osmolality, compatibility, and patient exposure
Citric acid	Buffering and pH control	Supports chemical stability
Hydrochloric acid	pH adjustment	Processing excipient
Sodium hydroxide	pH adjustment	Processing excipient
Water for injection	Vehicle	Parenteral-grade solvent

The formulation is designed for intravenous administration after dilution. The principal formulation constraint is not simple solubility. It is the combined control of pH, osmolality, chemical stability, container compatibility, dilution behavior, and infusion-line performance.

Sorbitol is commercially relevant because a reformulated product could use a different tonicity strategy. Potential alternatives include sodium chloride, dextrose, mannitol, or a lower-excipient aqueous system. Each alternative would require evaluation of osmolality, precipitation, degradation, extractables and leachables, and compatibility with commonly used infusion fluids.

What formulation patents could protect a next-generation Cardene product?

A conventional nicardipine injection has limited patent differentiation because the active ingredient and basic aqueous formulation are well established. A new product would need claims directed to a specific formulation, process, container, or administration system.

High-value formulation claim areas

1. Ready-to-use infusion formulation
   A stable nicardipine solution supplied at the final administration concentration could eliminate bedside dilution. Claims could cover concentration, pH, excipient identity, osmolality, and stability period.

2. Low-volume concentrated formulation
   A formulation with higher nicardipine concentration could reduce infusion volume for fluid-restricted patients. The principal technical issues would be solubility, precipitation after dilution, and local tolerability.

3. Preservative-free multidose or single-use presentation
   A preservative-free vial, ampoule, or bag could target neonatal, pediatric, neurocritical-care, and operating-room use.

4. Container-closure system
   Claims could cover polymer bags, multilayer films, low-sorption tubing, oxygen-barrier packaging, or light-protective systems.

5. Extended in-use stability
   Data showing stability after dilution in common infusion fluids, under refrigeration and room-temperature conditions, could support formulation and use claims.

6. Reduced adsorption and line compatibility
   Nicardipine delivery may be affected by tubing materials and administration sets. A formulation-container combination that limits drug loss could support a differentiated product.

7. Alternative tonicity system
   Replacing or reducing sorbitol could be commercially useful for patients with excipient intolerance or for institutions seeking standardized saline- or dextrose-based infusions.

A patent estate built only around routine excipient substitution would be vulnerable to obviousness challenges. Stronger protection would require a defined technical effect, such as materially improved stability, reduced adsorption, an unexpected compatibility result, or a clinically meaningful reduction in preparation errors.

How does Cardene I.V. compare with generic nicardipine injection?

Generic nicardipine injection is the principal competitive benchmark. The active ingredient, route, and broad clinical use are established. The commercial contest therefore shifts toward supply reliability, hospital contracting, packaging, preparation efficiency, and total cost of care.

Attribute	Cardene I.V.	Generic nicardipine injection	Differentiated opportunity
Active ingredient	Nicardipine hydrochloride	Nicardipine hydrochloride	Limited
Route	Intravenous	Intravenous	Limited
Preparation	Typically requires dilution	Often requires dilution	Ready-to-use product
Excipients	Sorbitol and citrate-based system	May use comparable or different excipients	Lower-sorbitol or alternative tonicity
Hospital workflow	Pharmacy or nursing preparation	Similar	Premixed bags or syringes
Patent leverage	Limited conventional leverage	Abbreviated-pathway competition	Formulation, container, process, or device claims
Purchasing decision	Clinical interchangeability and supply	Price and availability	Workflow and safety economics

The most credible commercial positioning is not a premium based only on a different excipient. It is a hospital-use proposition combining ready-to-administer packaging, reduced preparation steps, fewer manipulation points, predictable stability, and lower waste.

What FDA regulatory pathway applies to an excipient-led Cardene product?

A product that is compositionally and therapeutically equivalent to an approved nicardipine injection would generally pursue an abbreviated new drug application if it satisfies the applicable requirements for sameness, quality, bioequivalence where relevant, and labeling. A materially different formulation or presentation may require a 505(b)(2) application.

Likely FDA pathways

Product concept	Likely pathway	Key regulatory issue
Same formulation and presentation as approved injection	ANDA	Pharmaceutical equivalence and bioequivalence
Different excipients with same active and route	ANDA or 505(b)(2), depending on difference	Safety justification and equivalence
Ready-to-use premixed bag	505(b)(2) or ANDA depending on reference-product relationship	Product configuration, stability, administration
New concentration	505(b)(2) or ANDA depending on approved reference	Dose delivery and safety
Novel infusion device	505(b)(2), combination-product review may apply	Device performance and human factors
Modified-release oral capsule	505(b)(2) or ANDA	Pharmacokinetic profile and clinical bridging

The FDA labeling for Cardene I.V. identifies preparation, dilution, administration, storage, and incompatibility considerations. A new product should generate comparative data under actual hospital-use conditions, not only accelerated stability data. [1]

When does Cardene lose exclusivity, and what is the generic-entry risk?

Nicardipine is an established small-molecule product. The original composition-of-matter and early formulation exclusivities are not the primary commercial barriers today. Current competition is driven by abbreviated approvals, manufacturing capacity, institutional contracting, and supply continuity.

The relevant exclusivity categories are:

Exclusivity category	Current strategic relevance
Original composition-of-matter patent	Low for commercial planning
Original formulation patents	Low unless a specific enforceable listing remains
FDA regulatory exclusivity	Not the principal barrier
Orange Book-listed patents	Must be assessed against the current reference listing
Manufacturing and quality know-how	Moderate
Hospital contracts and supply history	Moderate to high
Formulation and device patents for a new product	Potentially high

A generic launch scenario is commercially plausible when the product is substitutable, supply is reliable, and the applicant can meet institutional purchasing requirements. A premium product can delay substitution only if it creates measurable operational value.

What is the Orange Book and Paragraph IV status of Cardene?

Cardene and nicardipine products should be evaluated through the current FDA Orange Book and Drugs@FDA records for the relevant reference product and dosage form. The key questions are whether any patents remain listed, whether they cover the specific injectable or capsule presentation, and whether an ANDA applicant has made a Paragraph IV certification.

Paragraph IV risk is likely to be concentrated in any newly patented formulation, delivery device, or ready-to-use presentation rather than in the basic nicardipine molecule. A sponsor commercializing a new Cardene formulation should expect possible challenges involving:

• Obviousness of excipient selection.
• Lack of unexpected results.
• Inherency of stability properties.
• Written-description support for concentration ranges.
• Anticipation by prior nicardipine injection formulations.
• Double-patenting against earlier formulation claims.
• Enablement of broad excipient and container claims.

For a new 505(b)(2) product, patent litigation risk may arise under the Hatch-Waxman framework if the product relies on listed patents associated with the reference product. A separate patent estate may still protect the improved formulation or presentation.

Which companies are challenging or competing with Cardene?

Competition includes the branded Cardene platform, generic nicardipine injection suppliers, generic capsule manufacturers, and alternative intravenous antihypertensives.

Relevant therapeutic and commercial competitors include:

Competitor category	Examples	Competitive effect
Generic nicardipine injection	Multiple abbreviated-approval suppliers	Price pressure and substitution
Clevidipine	Cleviprex	Competes for titratable ICU use
Esmolol	Generic and branded products	Competes in perioperative blood-pressure control
Labetalol	Generic products	Broad hospital substitution
Sodium nitroprusside	Generic products	Alternative rapid vasodilator
Hydralazine injection	Generic products	Lower-cost intermittent therapy

Clevidipine is the most direct branded comparator in the acute-care market. Its lipid-based formulation, short half-life, and ready-to-use presentation create a different excipient and workflow profile. Cardene can compete where clinicians value nicardipine’s established use, titratability, and familiarity. A ready-to-use nicardipine format would narrow the operational gap.

What commercial opportunities exist for Cardene excipients?

1. Ready-to-use nicardipine bags

Premixed bags could reduce dilution errors, pharmacy labor, and nursing preparation time. A differentiated product might be supplied in standard concentrations for ICU protocols, with a longer validated in-use period and clear compatibility data.

2. Low-sorbitol or sorbitol-free formulation

A reformulation could target institutions that prefer simpler excipient profiles. The opportunity depends on whether an alternative tonicity system maintains stability and avoids new safety or compatibility concerns.

3. Prefilled syringes

A prefilled syringe could address urgent bolus or short-duration administration scenarios, subject to approved dosing and labeling. The container system would need strong control of adsorption, extractables, and dose accuracy.

4. Pediatric and neonatal presentations

Smaller-volume presentations and reduced-excipient formulations could address pediatric and neonatal settings. This segment requires careful control of osmolality, dosing flexibility, preservative status, and manipulation volume.

5. Pharmacy-compounding platform

A standardized concentrate with validated dilution instructions, compatible bags, and administration sets could support hospital pharmacy contracts. The commercial model could include formulation, packaging, and workflow documentation.

6. Contract-manufactured hospital products

Hospitals and group purchasing organizations may value supply assurance more than brand recognition. A manufacturer with sterile-fill capacity, ready-to-use bag capability, and validated cold-chain or room-temperature stability could capture share through institutional tenders.

How strong is the Cardene patent estate?

The legacy Cardene estate is commercially weak relative to a newly developed formulation estate because nicardipine is an old small molecule with established injectable and oral dosage forms. The stronger assets are likely to be non-patent barriers:

• Sterile manufacturing validation.
• Container-closure qualification.
• Stability data.
• Hospital contracts.
• Supply-chain reliability.
• Proprietary premix configurations.
• Device integration.
• Regulatory execution.

A new formulation patent could be valuable if it protects a narrow but clinically relevant combination of concentration, pH, excipient, container, and stability performance. Broad claims covering routine aqueous nicardipine formulations would face substantial validity risk.

What manufacturing and intellectual-property barriers affect commercialization?

Sterile injectable manufacturing is the primary operational barrier. The critical capabilities include:

• Aseptic processing or terminal sterilization where compatible.
• Low-bioburden water systems.
• Sterile filtration validation.
• Particulate and container-closure testing.
• Extractables and leachables assessment.
• Photostability and oxygen-exposure studies.
• Compatibility with PVC and non-PVC infusion systems.
• Commercial-scale fill-finish capacity.
• Reliable supply of pharmaceutical-grade excipients.

Manufacturing know-how can support market position even where patent protection is limited. However, know-how alone does not prevent generic substitution. It must be combined with a product configuration that improves hospital economics or a regulatory pathway that delays direct competition.

What revenue exposure exists for a Cardene reformulation?

Revenue exposure is concentrated in acute-care institutions rather than retail pharmacy. The addressable value depends on hospital volume, infusion duration, contracting, and the proportion of use that moves from diluted concentrate to ready-to-use formats.

A reformulation can support premium pricing if it demonstrates:

• Lower pharmacy preparation cost.
• Reduced nursing manipulation.
• Fewer medication errors.
• Less product waste.
• Better inventory management.
• Longer usable shelf life.
• Improved availability during shortages.
• Lower line adsorption or dose variability.

A product that has the same preparation burden as generic nicardipine but uses a different excipient is unlikely to command durable premium pricing.

Key Takeaways

• Cardene is an established nicardipine hydrochloride product with limited legacy exclusivity leverage.
• The highest-value opportunity is intravenous reformulation, not conventional oral capsules.
• Ready-to-use bags, prefilled syringes, low-sorbitol systems, and compatibility-focused packaging are the most credible product concepts.
• Excipient substitution alone is weak commercial differentiation unless it produces a measurable stability, safety, or workflow benefit.
• A new product may use an ANDA or 505(b)(2) pathway depending on the formulation, concentration, presentation, and reference-product relationship.
• Generic competition is a persistent risk because nicardipine is an established small molecule.
• Manufacturing capability, hospital contracting, sterile-fill capacity, and supply reliability may be more important than legacy patents.
• The strongest new patent claims would combine formulation composition with container, stability, administration, or compatibility limitations.

FAQs

Can sorbitol be removed from Cardene I.V.?

Potentially, but removal would require a replacement tonicity and stability strategy. The reformulated product would need comparative quality, compatibility, and clinical regulatory support.

Is a premixed nicardipine infusion patentable?

It can be patentable if the product has a novel and non-obvious combination of concentration, excipients, container, stability, or administration characteristics. A premix concept alone may be insufficient.

Does a ready-to-use Cardene product reduce generic competition?

It can reduce direct substitution if the product has distinct regulatory, patent, or contracting advantages. It does not prevent competition from another ready-to-use generic or 505(b)(2) product.

Which excipient is most commercially important in Cardene I.V.?

Sorbitol is the most commercially relevant because it contributes to tonicity and influences the design of alternative formulations. Citric acid remains important for pH and stability control.

Is the oral Cardene capsule a major reformulation opportunity?

The opportunity is narrower than for the injection. A modified-release, adherence-oriented, or patient-specific capsule could create differentiation, but generic oral competition and limited acute-care value reduce its attractiveness.

References

1. U.S. Food and Drug Administration. (n.d.). Cardene I.V. (nicardipine hydrochloride) injection prescribing information. FDA.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. FDA.
4. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.